Atlas Trials

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Clinical trial NCT03804515 · TERMINATED

Trial details

NCT number
NCT03804515
Sponsor
Spectrum Pharmaceuticals, Inc
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumor
Start date
2019-06-25
Primary completion
2020-02-20
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.